Efficacy and Safety of tDCS and tACS in Treatment of Major Depressive Disorder: A Randomized, Double-Blind, Factorial Placebo-Controlled Study Design

Yuxin Huang,1 Linjie Shen,1 Jia Huang,1 Xianrong Xu,2 Yong Wang,1 Hua Jin1 1Department of Outpatient, Shanghai Mental Health Center, Shanghai, People’s Republic of China; 2School of Public Health, Hangzhou Normal University, Hnagzhou, Zhejiang Province, People’s Republic of China...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Huang Y, Shen L, Huang J, Xu X, Wang Y, Jin H
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	transcranial direct current stimulation (tdcs) transcranial alternating current stimulation (tacs) electrical stimulation major depressive disorder(mdd) Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/42a2514e2f034e91aa8010e93a6e01bc
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:42a2514e2f034e91aa8010e93a6e01bc
record_format	dspace
spelling	oai:doaj.org-article:42a2514e2f034e91aa8010e93a6e01bc2021-12-02T17:04:44ZEfficacy and Safety of tDCS and tACS in Treatment of Major Depressive Disorder: A Randomized, Double-Blind, Factorial Placebo-Controlled Study Design1178-2021https://doaj.org/article/42a2514e2f034e91aa8010e93a6e01bc2021-05-01T00:00:00Zhttps://www.dovepress.com/efficacy-and-safety-of-tdcs-and-tacs-in-treatment-of-major-depressive--peer-reviewed-fulltext-article-NDThttps://doaj.org/toc/1178-2021Yuxin Huang,1 Linjie Shen,1 Jia Huang,1 Xianrong Xu,2 Yong Wang,1 Hua Jin1 1Department of Outpatient, Shanghai Mental Health Center, Shanghai, People’s Republic of China; 2School of Public Health, Hangzhou Normal University, Hnagzhou, Zhejiang Province, People’s Republic of ChinaCorrespondence: Yong WangDepartment of Outpatient, Shanghai Mental Health Center, No. 600 Wanping South Road, Xuhui District, Shanghai, People’s Republic of ChinaTel +86-18017311332Email tianlai1977@yeah.netBackground: Transcranial direct current stimulation (tDCS) and transcranial alternating current stimulation (tACS) are regarded as promising antidepressant treatments.Objective: To compare the efficacy and safety of tDCS, tACS, escitalopram, and placebo/sham stimulation controls.Design: Randomized, parallel, double-blind, placebo-controlled study.Methods: Sample sizes were calculated based on data from previous similar studies. Eligible non-treatment-resistant-depressive outpatient subjects with moderate-to-severe depression (HRDS ≥ 17) are randomized to receive (1) tDCS + placebo; (2) tACS + placebo; (3) escitalopram + placebo; or (4) sham stimulation + placebo. The intensity of electricity is 2 mA, lasting for 30 minutes over two consecutive working days (10 sessions in total). The medication lasts for 6 weeks. The primary outcome measure was the response rates within 6 weeks (week 6 is also the endpoint of the study), and secondary outcome measures included changes in other clinical measurements. Safety and acceptability are measured by adverse event rates and dropout rates. Exploring outcome consist of the performance of cognitive battery as well as neurophysiology results.Conclusion: To the best of our knowledge, the present study is the first double-blind controlled study comparing tDCS, tACS, and clinically used antidepressants, which will provide further evidence for their efficacy and safety in possible clinical applications.Keywords: transcranial direct current stimulation, tDCS, transcranial alternating current stimulation, tACS, electrical stimulation, major depressive disorder, MDDHuang YShen LHuang JXu XWang YJin HDove Medical Pressarticletranscranial direct current stimulation (tdcs)transcranial alternating current stimulation (tacs)electrical stimulationmajor depressive disorder(mdd)Neurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 17, Pp 1459-1468 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	transcranial direct current stimulation (tdcs) transcranial alternating current stimulation (tacs) electrical stimulation major depressive disorder(mdd) Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	transcranial direct current stimulation (tdcs) transcranial alternating current stimulation (tacs) electrical stimulation major depressive disorder(mdd) Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Huang Y Shen L Huang J Xu X Wang Y Jin H Efficacy and Safety of tDCS and tACS in Treatment of Major Depressive Disorder: A Randomized, Double-Blind, Factorial Placebo-Controlled Study Design
description	Yuxin Huang,1 Linjie Shen,1 Jia Huang,1 Xianrong Xu,2 Yong Wang,1 Hua Jin1 1Department of Outpatient, Shanghai Mental Health Center, Shanghai, People’s Republic of China; 2School of Public Health, Hangzhou Normal University, Hnagzhou, Zhejiang Province, People’s Republic of ChinaCorrespondence: Yong WangDepartment of Outpatient, Shanghai Mental Health Center, No. 600 Wanping South Road, Xuhui District, Shanghai, People’s Republic of ChinaTel +86-18017311332Email tianlai1977@yeah.netBackground: Transcranial direct current stimulation (tDCS) and transcranial alternating current stimulation (tACS) are regarded as promising antidepressant treatments.Objective: To compare the efficacy and safety of tDCS, tACS, escitalopram, and placebo/sham stimulation controls.Design: Randomized, parallel, double-blind, placebo-controlled study.Methods: Sample sizes were calculated based on data from previous similar studies. Eligible non-treatment-resistant-depressive outpatient subjects with moderate-to-severe depression (HRDS ≥ 17) are randomized to receive (1) tDCS + placebo; (2) tACS + placebo; (3) escitalopram + placebo; or (4) sham stimulation + placebo. The intensity of electricity is 2 mA, lasting for 30 minutes over two consecutive working days (10 sessions in total). The medication lasts for 6 weeks. The primary outcome measure was the response rates within 6 weeks (week 6 is also the endpoint of the study), and secondary outcome measures included changes in other clinical measurements. Safety and acceptability are measured by adverse event rates and dropout rates. Exploring outcome consist of the performance of cognitive battery as well as neurophysiology results.Conclusion: To the best of our knowledge, the present study is the first double-blind controlled study comparing tDCS, tACS, and clinically used antidepressants, which will provide further evidence for their efficacy and safety in possible clinical applications.Keywords: transcranial direct current stimulation, tDCS, transcranial alternating current stimulation, tACS, electrical stimulation, major depressive disorder, MDD
format	article
author	Huang Y Shen L Huang J Xu X Wang Y Jin H
author_facet	Huang Y Shen L Huang J Xu X Wang Y Jin H
author_sort	Huang Y
title	Efficacy and Safety of tDCS and tACS in Treatment of Major Depressive Disorder: A Randomized, Double-Blind, Factorial Placebo-Controlled Study Design
title_short	Efficacy and Safety of tDCS and tACS in Treatment of Major Depressive Disorder: A Randomized, Double-Blind, Factorial Placebo-Controlled Study Design
title_full	Efficacy and Safety of tDCS and tACS in Treatment of Major Depressive Disorder: A Randomized, Double-Blind, Factorial Placebo-Controlled Study Design
title_fullStr	Efficacy and Safety of tDCS and tACS in Treatment of Major Depressive Disorder: A Randomized, Double-Blind, Factorial Placebo-Controlled Study Design
title_full_unstemmed	Efficacy and Safety of tDCS and tACS in Treatment of Major Depressive Disorder: A Randomized, Double-Blind, Factorial Placebo-Controlled Study Design
title_sort	efficacy and safety of tdcs and tacs in treatment of major depressive disorder: a randomized, double-blind, factorial placebo-controlled study design
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/42a2514e2f034e91aa8010e93a6e01bc
work_keys_str_mv	AT huangy efficacyandsafetyoftdcsandtacsintreatmentofmajordepressivedisorderarandomizeddoubleblindfactorialplacebocontrolledstudydesign AT shenl efficacyandsafetyoftdcsandtacsintreatmentofmajordepressivedisorderarandomizeddoubleblindfactorialplacebocontrolledstudydesign AT huangj efficacyandsafetyoftdcsandtacsintreatmentofmajordepressivedisorderarandomizeddoubleblindfactorialplacebocontrolledstudydesign AT xux efficacyandsafetyoftdcsandtacsintreatmentofmajordepressivedisorderarandomizeddoubleblindfactorialplacebocontrolledstudydesign AT wangy efficacyandsafetyoftdcsandtacsintreatmentofmajordepressivedisorderarandomizeddoubleblindfactorialplacebocontrolledstudydesign AT jinh efficacyandsafetyoftdcsandtacsintreatmentofmajordepressivedisorderarandomizeddoubleblindfactorialplacebocontrolledstudydesign
_version_	1718381844743847936

Efficacy and Safety of tDCS and tACS in Treatment of Major Depressive Disorder: A Randomized, Double-Blind, Factorial Placebo-Controlled Study Design

Ejemplares similares